Oliger Christy J.
SEC-identified person · CIK 1822092 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nuvalent, Inc. NUVL | Director | filed 2025–2026 |
| Karyopharm Therapeutics Inc. KPTI | Director | filed 2020–2026 |
| Vera Therapeutics, Inc. VERA | Director | filed 2024–2026 |
| Replimune Group, Inc. REPL | Director | filed 2021–2026 |
| Lava Therapeutics NV LVTX | Director | filed 2025–2025 |
| Rayzebio, Inc. RYZB | Director | filed 2023–2024 |
| Reata Pharmaceuticals INC RETA | Director | filed 2021–2023 |
| Sierra Oncology, Inc. SRRA | Director | filed 2021–2022 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.